Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-03

FDA Approved: REYVOW — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved Eli Lilly's supplemental application for Reyvow (lasmiditan).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REYVOW (Lasmiditan)

Snippet

SUPPL AP for REYVOW (LASMIDITAN)